دورية أكاديمية
Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children’s Oncology Group
| العنوان: | Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children’s Oncology Group |
|---|---|
| المؤلفون: | Cash, Thomas, McIlvaine, Elizabeth, Krailo, Mark D., Lessnick, Stephen L., Lawlor, Elizabeth R., Laack, Nadia, Sorger, Joel, Marina, Neyssa, Grier, Holcombe E., Granowetter, Linda, Womer, Richard B., DuBois, Steven G. |
| بيانات النشر: | John Wiley and Sons |
| سنة النشر: | 2016 |
| المجموعة: | University of Michigan: Deep Blue |
| مصطلحات موضوعية: | soft‐tissue Ewing sarcoma, gene profiling, gene expression, extraskeletal Ewing sarcoma, extraosseous, prognosis, Pediatrics, Health Sciences |
| الوصف: | BackgroundThe prognostic significance of having extraskeletal (EES) versus skeletal Ewing sarcoma (ES) in the setting of modern chemotherapy protocols is unknown. The purpose of this study was to compare the clinical characteristics, biologic features, and outcomes for patients with EES and skeletal ES.MethodsPatients had localized ES and were treated on two consecutive protocols using five‐drug chemotherapy (INT‐0154 and AEWS0031). Patients were analyzed based on having an extraskeletal (n = 213) or skeletal (n = 826) site of tumor origin. Event‐free survival (EFS) was estimated using the Kaplan–Meier method, compared using the log‐rank test, and modeled using Cox multivariate regression.ResultsPatients with extraskeletal ES (EES) were more likely to have axial tumors (72% vs. 55%; P < 0.001), less likely to have tumors >8 cm (9% vs. 17%; P < 0.01), and less likely to be white (81% vs. 87%; P < 0.001) compared to patients with skeletal ES. There was no difference in key genomic features (type of EWSR1 translocation, TP53 mutation, CDKN2A mutation/loss) between groups. After controlling for age, race, and primary site, EES was associated with superior EFS (hazard ratio = 0.69; 95% confidence interval: 0.50–0.95; P = 0.02). Among patients with EES, age ≥18, nonwhite race, and elevated baseline erythrocyte sedimentation rate were independently associated with inferior EFS.ConclusionClinical characteristics, but not key tumor genomic features, differ between EES and skeletal ES. Extraskeletal origin is a favorable prognostic factor, independent of age, race, and primary site. ; Peer Reviewed ; http://deepblue.lib.umich.edu/bitstream/2027.42/134112/1/pbc26096.pdfTest ; http://deepblue.lib.umich.edu/bitstream/2027.42/134112/2/pbc26096_am.pdfTest |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | unknown |
| تدمد: | 1545-5009 1545-5017 |
| العلاقة: | Cash, Thomas; McIlvaine, Elizabeth; Krailo, Mark D.; Lessnick, Stephen L.; Lawlor, Elizabeth R.; Laack, Nadia; Sorger, Joel; Marina, Neyssa; Grier, Holcombe E.; Granowetter, Linda; Womer, Richard B.; DuBois, Steven G. (2016). "Comparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children’s Oncology Group." Pediatric Blood & Cancer 63(10): 1771-1779.; http://hdl.handle.net/2027.42/134112Test; Pediatric Blood & Cancer; Ilić I, Manojlović S, Cepulić M, Orlić D, Seiwerth S. Osteosarcoma and Ewing’s sarcoma in children and adolescents: Retrospective clinicopathological study. Croat Med J. 2004; 45: 740 – 745.; Volchenboum SL, Andrade J, Huang L, et al. Gene expression profiling of Ewing sarcoma tumours reveals the prognostic importance of tumour–stromal interactions: A report from the Children’s Oncology Group. J Path Clin Res. 2015; 1: 83 – 94.; Marubini E, Valsecchi MG. Analysing Survival Data from Clinical Trials and Observational Studies. New York: John Wiley and Sons; 1995.; Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496 – 509.; Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4: 44 – 57.; Orr WS, Denbo JW, Billups CA, et al. Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: Review of St. Jude Children’s Research Hospital experience. Ann Surg Oncol. 2012; 19: 3816 – 3822.; El Weshi A, Allam A, Ajarim D, et al. Extraskeletal Ewing’s sarcoma family of tumours in adults: Analysis of 57 patients from a single institution. Clin Oncol. 2010; 22: 374 – 381.; van den Berg H, Heinen RC, van der Pal HJ, Merks JH. Extra‐osseous Ewing sarcoma. Pediatr Hematol Oncol. 2009; 26: 175 – 185.; DuBois SG, Krailo MD, Gebhardt MC, et al. Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children’s Oncology Group. Cancer. 2015; 121: 467 – 475.; Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing’s sarcoma Study Group. J Clin Oncol. 2000; 18: 3108 – 3114.; Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant chemotherapy: Analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000; 18: 4 – 11.; Lee J, Hoang BH, Ziogas A, Zell JA. Analysis of prognostic factors in Ewing sarcoma using a population‐based cancer registry. Cancer. 2010; 116: 1964 – 1973.; Strojnik T, Smigoc T, Lah TT. Prognostic value of erythrocyte sedimentation rate and C‐reactive protein in the blood of patients with glioma. Anticancer Res. 2014; 34: 339 – 347.; Sengupta S, Lohse CM, Cheville JC, et al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer. 2006; 106: 304 – 312.; Alexandrakis MG, Passam FH, Ganotakis ES, et al. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin‐6 (IL‐6) and acute phase protein levels in multiple myeloma. Clin Lab Haematol. 2003; 25: 41 – 46.; Johansson JE, Sigurdsson T, Holmberg L, Bergström R. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population‐based consecutive cases. Cancer. 1992; 7: 1556 – 1563.; Henry‐Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early‐stage Hodgkin disease: The EORTC Lymphoma Cooperative Group. Ann Intern Med. 1991; 114: 361 – 365.; Oberlin O, Deley MC, Bui BN, et al. French Society of Paediatric Oncology. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: The third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer. 2001; 85: 1646 – 1654.; Aparicio J, Munárriz B, Pastor M, et al. Long‐term follow‐up and prognostic factors in Ewing’s sarcoma: A multivariate analysis of 116 patients from a single institution. Oncology. 1998; 55: 20 – 26.; Bacci G, Ferrari S, Rosito P, et al. Ewing’s sarcoma of the bone. Anatomoclinical study of 424 cases. Minerva Pediatr. 1992; 44: 345 – 359.; Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140: 883 – 899.; Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860 – 867.; Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res. 2006; 4: 221 – 233.; Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011; 144: 646 – 674.; Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. World Health Organization Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2013.; Italiano A, Sung YS, Zhang L, et al. High prevalence of CIC fusion with double‐homeobox (DUX4) transcription factors in EWSR1‐negative undifferentiated small blue round cell sarcomas. Genes Chromosomes Cancer. 2012; 51: 207 – 218.; Pierron G, Tirode F, Lucchesi C, et al. A new subtype of bone sarcoma defined by BCOR‐CCNB3 gene fusion. Nat Genet. 2012; 44: 461 – 466.; Sugita S, Arai Y, Tonooka A, et al. A novel CIC‐FOXO4 gene fusion in undifferentiated small round cell sarcoma: A genetically distinct variant of Ewing‐like sarcoma. Am J Surg Pathol. 2014; 38: 1571 – 1576.; Antonescu C. Round cell sarcomas beyond Ewing: Emerging entities. Histopathology 2014; 64: 26 – 37.; Specht K, Sung YS, Zhang L, Richter GH, Fletcher CD, Antonescu CR. Distinct transcriptional signature and immunoprofile of CIC‐DUX4 fusion‐positive round cell tumors compared to EWSR1‐rearranged ewing sarcomas: Further evidence toward distinct pathologic entities. Genes Chromosomes Cancer. 2014; 53: 622 – 663.; Delaplace M, Lhommet C, de Pinieux G, Vergier B, de Muret A, Machet L. Primary cutaneous Ewing sarcoma: A systematic review focused on treatment and outcome. Br J Dermatol. 2012; 166: 721 – 726.; Applebaum MA, Worch J, Matthay KK, et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer. 2011; 117: 3027 – 3032.; Granowetter L, Womer R, Devidas M, et al. Dose‐intensified compared with standard chemotherapy for non‐metastatic Ewing sarcoma family of tumors: A Children’s Oncology Group Study. J Clin Oncol. 2009; 27: 2536 – 2541.; Castex MP, Rubie H, Stevens MC, et al. Extraosseous localized ewing tumors: Improved outcome with anthracyclines—The French society of pediatric oncology and international society of pediatric oncology. J Clin Oncol. 2007; 25: 1176 – 1182.; Raney RB, Asmar L, Newton WA Jr, et al. Ewing’s sarcoma of soft tissues in childhood: A report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991. J Clin Oncol. 1997; 15: 574 – 582.; Gururangan S, Marina NM, Luo X, et al. Treatment of children with peripheral primitive neuroectodermal tumor or extraosseous Ewing’s tumor with Ewing’s‐directed therapy. J Pediatr Hematol Oncol. 1998; 20: 55 – 61.; Lee JA, Kim DH, Lim JS, et al. Soft‐tissue Ewing sarcoma in a low‐incidence population: Comparison to skeletal Ewing sarcoma for clinical characteristics and treatment outcome. Jpn J Clin Oncol. 2010; 40: 1060 – 1067.; Biswas B, Shukla NK, Deo SV, et al. Evaluation of outcome and prognostic factors in extraosseous Ewing sarcoma. Pediatr Blood Cancer. 2014; 61: 1925 – 1931.; Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval‐compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children’s Oncology Group. J Clin Oncol. 2012; 30: 4148 – 4154.; Karski EE, McIlvaine E, Segal MR, et al. Identification of discrete prognostic groups in Ewing sarcoma. Pediatr Blood Cancer. 2016; 63: 47 – 53.; van Doorninck JA, Ji L, Schaub B, et al. Current treatment protocols have eliminated the prognostic advantage of type 1 fusions in Ewing sarcoma: A report from the Children’s Oncology Group. J Clin Oncol. 2010; 28: 1989 – 1994.; Lerman DM, Monument MJ, McIlvaine E, et al. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015; 62: 759 – 765. |
| DOI: | 10.1002/pbc.26096 |
| الإتاحة: | https://doi.org/10.1002/pbc.26096Test http://hdl.handle.net/2027.42/134112Test |
| حقوق: | IndexNoFollow |
| رقم الانضمام: | edsbas.879C4674 |
| قاعدة البيانات: | BASE |
| تدمد: | 15455009 15455017 |
|---|---|
| DOI: | 10.1002/pbc.26096 |